296 related articles for article (PubMed ID: 15246280)
21. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.
Laassri M; Meseda CA; Williams O; Merchlinsky M; Weir JP; Chumakov K
J Med Virol; 2007 Jun; 79(6):791-802. PubMed ID: 17457926
[TBL] [Abstract][Full Text] [Related]
22. Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera.
Ward BM; Moss B
J Virol; 2001 May; 75(10):4802-13. PubMed ID: 11312352
[TBL] [Abstract][Full Text] [Related]
23. Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.
Yokote H; Shinmura Y; Kanehara T; Maruno S; Kuranaga M; Matsui H; Hashizume S
Vaccine; 2015 Nov; 33(45):6112-9. PubMed ID: 26241947
[TBL] [Abstract][Full Text] [Related]
24. Selection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library.
Shin YW; Chang KH; Hong GW; Yeo SG; Jee Y; Kim JH; Oh MD; Cho DH; Kim SH
J Microbiol Biotechnol; 2019 Apr; 29(4):651-657. PubMed ID: 30856707
[TBL] [Abstract][Full Text] [Related]
25. A mutational analysis of the vaccinia virus B5R protein.
Mathew EC; Sanderson CM; Hollinshead R; Smith GL
J Gen Virol; 2001 May; 82(Pt 5):1199-1213. PubMed ID: 11297695
[TBL] [Abstract][Full Text] [Related]
26. The immune response to vaccinia virus is significantly reduced after scarification with TK- recombinants as compared to wild-type virus.
Phillpotts RJ; Lescott T; Gates AJ; Jones L
Acta Virol; 2000; 44(3):151-6. PubMed ID: 11155357
[TBL] [Abstract][Full Text] [Related]
27. Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination.
Wolffe EJ; Isaacs SN; Moss B
J Virol; 1993 Aug; 67(8):4732-41. PubMed ID: 8331727
[TBL] [Abstract][Full Text] [Related]
28. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
29. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope.
Isaacs SN; Wolffe EJ; Payne LG; Moss B
J Virol; 1992 Dec; 66(12):7217-24. PubMed ID: 1433514
[TBL] [Abstract][Full Text] [Related]
30. Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.
Meseda CA; Campbell J; Kumar A; Garcia AD; Merchlinsky M; Weir JP
PLoS One; 2013; 8(6):e67984. PubMed ID: 23785523
[TBL] [Abstract][Full Text] [Related]
31. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
32. Replacing the SCR domains of vaccinia virus protein B5R with EGFP causes a reduction in plaque size and actin tail formation but enveloped virions are still transported to the cell surface.
Rodger G; Smith GL
J Gen Virol; 2002 Feb; 83(Pt 2):323-332. PubMed ID: 11807225
[TBL] [Abstract][Full Text] [Related]
33. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions.
Katz E; Wolffe EJ; Moss B
J Virol; 1997 Apr; 71(4):3178-87. PubMed ID: 9060681
[TBL] [Abstract][Full Text] [Related]
34. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.
Gurt I; Abdalrhman I; Katz E
Antiviral Res; 2006 Mar; 69(3):158-64. PubMed ID: 16406098
[TBL] [Abstract][Full Text] [Related]
35. Development of a novel vaccinia-neutralization assay based on reporter-gene expression.
Manischewitz J; King LR; Bleckwenn NA; Shiloach J; Taffs R; Merchlinsky M; Eller N; Mikolajczyk MG; Clanton DJ; Monath T; Weltzin RA; Scott DE; Golding H
J Infect Dis; 2003 Aug; 188(3):440-8. PubMed ID: 12870127
[TBL] [Abstract][Full Text] [Related]
36. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation.
Vanderplasschen A; Hollinshead M; Smith GL
J Gen Virol; 1997 Aug; 78 ( Pt 8)():2041-8. PubMed ID: 9267005
[TBL] [Abstract][Full Text] [Related]
37. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement.
Lustig S; Fogg C; Whitbeck JC; Moss B
Virology; 2004 Oct; 328(1):30-5. PubMed ID: 15380355
[TBL] [Abstract][Full Text] [Related]
38. Intracellular localization of vaccinia virus extracellular enveloped virus envelope proteins individually expressed using a Semliki Forest virus replicon.
Lorenzo MM; Galindo I; Griffiths G; Blasco R
J Virol; 2000 Nov; 74(22):10535-50. PubMed ID: 11044098
[TBL] [Abstract][Full Text] [Related]
39. Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
Kirn DH; Wang Y; Liang W; Contag CH; Thorne SH
Cancer Res; 2008 Apr; 68(7):2071-5. PubMed ID: 18381410
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review.
Hopkins RJ; Lane JM
Clin Infect Dis; 2004 Sep; 39(6):819-26. PubMed ID: 15472814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
